马来西亚私立医疗保健领域初治早期可切除非小细胞肺癌患者的治疗启动时间分析

06 November 2025


Anand Sachithanandan, FRCSI(C-Th)1,2,3, Hoh Hong Huat, PhD4, Lee Joyin, BSc4, Lim Yi Shwen, BSc4, Naim Che Kamaruddin, MSc4, Fatin Najihah Muhammad Lutfi, MSc5, Yong Wong Wai Shieh, BSc5, Siti Ayuni Hassanudin, , Ten Yi Yang, PhD5, Lam Mynn Dee, MD5, Janelle Wee Chia Ern4,6, Deva Rani Raja Sakar, BSc4, Shobana Satchithananthan4,7  

下载完整 PDF 在此查看研究
复制引用
已复制！

摘要

Introduction

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality in Malaysia, with 95% of cases diagnosed at advanced stages. Beyond screening for early detection, timely intervention is critical for optimal outcomes in early-stage, resectable NSCLC (e-NSCLC). Delays in the diagnostic, staging and referral pathway, measured as time-to-treatment initiation (TTI), are associated with poorer survival. This contemporary realworld study is the first to evaluate TTI in a cohort of Malaysian patients with e-NSCLC.

Materials and methods

This is a retrospective study of 124 consecutive treatment-naive e-NSCLC patients who had a minimally invasive curative anatomical lung resection (lobectomy or segmentectomy) and systematic mediastinal nodal dissection between January 2021 and December 2024 at two tertiary private hospitals. Medical records were reviewed to capture key timepoints across three phases of care. The primary analysis (n=124) focused on demographics and assessed the timeline from initial general practitioner (GP) to specialist consultation, diagnosis, and definitive surgery. These patients were evaluated after surgical discharge to validation of histopathology and nextgeneration sequencing (NGS) reports, and oncology review. Patients who received adjuvant therapy were included in a secondary analysis to examine timelines from NGS report validation and oncology review to initiation of adjuvant therapy.

Results

The median time from the GP referral to surgery was 30.0 ± 24.5 days; GP consultation to specialist referral took 7.5 ± 17.0 days, specialist review to surgeon consultation took another 10.0 ± 16.3 days. Biopsy and staging PET-CT were completed within 3.0 ± 20.9 and 3.0 ± 20.5 days, respectively, from the initial specialist consultation. Definitive curative-intent surgery was performed 7.5 ± 13.1 days from the first cardiothoracic surgical consult and 18 ± 23.3 days following a confirmed histological diagnosis of NSCLC. The median interval from specialist review to definitive surgery was 20.0 ± 20.2 days. The median time from surgery to discharge and reporting of NGS results was 5.0 ± 2.6 days and 12.0 ± 7.7 days, respectively. Patients were seen at the first post-surgical review within 7.0 ± 3.7 days following discharge, while oncology review occurred at 19.0 ± 16.2 days post-surgery. For patients eligible for adjuvant therapy, treatment commenced 14.5 ± 11.4 days following the oncology review.

Conclusion

TTI is known to prognosticate recurrence-free and overall survival for e-NSCLC. This contemporary realworld experience from two leading tertiary cancer centres demonstrates the agility and efficiency of Malaysian private healthcare for prompt diagnosis, meticulous staging and timely, curative-intent definitive surgery for e-NSCLC, aligning with global benchmarks. Our study suggests, if prioritised, a swift TTI is highly achievable with appropriate expertise and coordinated resources, and should be incorporated as a deliverable national quality metric to drive improved outcomes for potentially curable e-NSCLC.

参考资料

  1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553(7689): 446–54.
  2. National Cancer Institute. Summary of Malaysia National Cancer Registry Report 2017-2021. [cited July 2025]. Accessed from: https://nci.moh.gov.my/images/pdf_folder/SUMMARY-OFMALAYSIA-NATIONAL-CANCER-REGISTRY-REPORT-20172021.pdf.
  3. Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive Summary: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2013; 143 Suppl: S7-37.
  4. Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax 2009; 64(9): 749-56.
  5. Azzouqa AG, Chen R, Lou Y, Ailawadhi S, Manochakian R. Impact of time to treatment initiation (TTI) on survival of patients with newly diagnosed non-small cell lung cancer (NSCLC). J Clin Oncol 2019; 37 Suppl: S9058.
  6. Teng J, Liu Y, Xia J, Luo Y, Zou H, Wang H. Impact of time-totreatment initiation on survival in single primary non-small cell lung Cancer: A population-based study. Heliyon. 2023 Sep 2; 9(9): e19750. doi: 10.1016/j.heliyon.2023.e19750. PMID: 37810045; PMCID: PMC10559072.
  7. Wang L, Correa CR, Zhao L, Hayman J, Kalemkerian GP, Lyons S et al. The effect of radiation dose and chemotherapy on overall survival in 237 patients with stage III non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 73(5): 1383-90.
  8. Loh L-C, Chan L-Y, Tan R-Y, Govindaraju S, Ratnavelu K, Kumar S, et al. Time delay and its effect on survival in Malaysian patients with non-small cell lung carcinoma. Malays J Med Sci 2006; 13(1): 37-42.
  9. Anggondowati T, Ganti AK, Islam KMM. Impact of time-totreatment on overall survival of non-small cell lung cancer patients—an analysis of the national cancer database. Transl Lung Cancer Res 2020; 9(4): 1202-11.
  10. Chelapareddy LR, Beheshti M, Naha K, Zachary I. Time to treatment initiation: An assessment of trends in delays in patients with lung cancer across Missouri. J Clin Oncol 2024; 42 Suppl: S11186.
  11. Saw SPL, Chua KLM, Ong BH, Lim DWT, Lai GGY, Tan DSW, et al. Multidisciplinary lung cancer clinic: An emerging model of care. Ann Acad Med Singap 2022; 51(12): 793-5.
  12. Cushman TR, Jones B, Akhavan D, Rusthoven CG, Verma V, Salgia R, et al. The Effects of Time to Treatment Initiation for Patients with Non–small-cell Lung Cancer in the United States. Clin Lung Cancer 2021; 22(1): 84-97.
  13. Valsecchi C, Franza A, Bogani G, Rolli L, Ferrari M, Leuzzi G, et al. Effectiveness of multi-disciplinary team management on 5year overall survival for patients with stage III lung cancer. J Thorac Dis 2024; 16(8): 5086-96.
  14. Sachithanandan A, Mohammad Razi AA, Krishnasamy S, Chan KMJ, Lam HY, Diong NC, Sathiamurthy N, Ooi ASW, Soon SY. Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable nonsmall cell lung cancer (NSCLC) in Malaysia. Transl Lung Cancer Res 2025; 14(7): 2403-26.
  15. Mayer N, Boschetti L, Scarci M, Cioffi U, Simone MD, Schnider M, et al. Brain Imaging in Patients with Non-Small Cell Lung Cancer—A Systematic Review. J Clin Med 2025; 14(3): 708.
  16. Herbst RS, Wu Y-L, John T, Grohe C, Majem M, Wang J, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial. J Clin Oncol 2023; 41(10): 1830-40. 
  17. Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 2023; 389(2): 137-47.
  18. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26; 386(21): 1973-85.
  19. Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, MeadowsShropshire S, Fiore J, Bhatia S, Girard N; CheckMate 816 Investigators. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931. Epub ahead of print. PMID: 40454642.
  20. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023; 389(6): 491-503. 
  21. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable nonsmall-cell lung cancer. N Engl J Med 2023; 389(18): 1672-84.
  22. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024; 390(19): 1756-69.
  23. He J, Tsuboi M, Weder W, Chen K-N, Hochmair MJ, Shih J-Y, et al. Neoadjuvant osimertinib for resectable EGFR-mutated nonsmall cell lung cancer. J Clin Oncol 2025; JCO2500883.
  24. Tørring ML, Frydenberg M, Hansen RP, Olesen F, Vedsted P. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. Eur J Cancer 2013; 49(9): 2187-98.
  25. González-Barcala FJ, García-Prim JM, Alvarez-Dobaño JM, Moldes-Rodríguez M, García-Sanz MT, Pose-Reino A, et al. Effect of delays on survival in patients with lung cancer. Clin Transl Oncol 2010; 12(12): 836-42.
  26. Skaug K, Eide GE, Gulsvik A. Predictors of long-term survival of lung cancer patients in a Norwegian community. Clin Respir J 2011; 5(1): 50-8. 

引用

Sachithanandan A, Hoh HH, Lee J, Lim YS, Naim CK, Lutfi FNM, Yong WWS, Hassanudin SA, Ten YY, Lam MD, Wee JCE, Deva DR, Satchithananthan S. A time-to-treatment initiation analysis for treatment-naive early-stage resectable non-small cell lung cancer patients in the Malaysian private healthcare sector. Med J Malaysia. 2025 Nov;80(6):716-723. PMID: 41328828.

复制引用 已复制！
下载完整 PDF 在此查看研究